Cytochrome (CYP) P450 is now recognized as one of the three primary branches of the biomedically important arachidonate cascade together with the more intensively studied cyclooxygenase and lipoxygenase pathways. The primary metabolites of the cascade are subject to further enzymatic and non-enzymatic transformations resulting in a rich spectrum of bioactive products. Over the past decade, the participants of this Program Project have cogently demonstrated the relevance of the CYP cascade to renal physiology. In particular, products from the epoxygenase and omega/omega-I pathways have been implicated in vasoreactivity, ion and water transport, hormonal signaling, and hypertension. To expedite current investigations into the biogenesis, regulation, storage, metabolism, and mechanism of action of physiologically significant renal eicosanoids, this project proposes to: (1) Devise and conduct unambiguous, stereocontrolled total syntheses of bioactive arachidonate metabolites that influence kidney function. (2) Elucidate the structure-activity relationships (SAR) in bioactive renal eicosanoids. (3) Prepare synthetic eicosanoid analogs with modified chemical, metabolic, and/or pharmacological properties for use as selective agonists or antagonists as well as for the characterization, localization, and isolation of macromolecules that bind/recognize renal eicosanoids. (4) Design and evaluate selective metabolism inhibitors for use in vitro and/or in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
2P01DK038226-18A1
Application #
6813197
Study Section
Special Emphasis Panel (ZDK1-GRB-2 (M2))
Project Start
2004-07-01
Project End
2009-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
18
Fiscal Year
2004
Total Cost
$146,638
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Elijovich, Fernando; Milne, Ginger L; Brown, Nancy J et al. (2018) Two Pools of Epoxyeicosatrienoic Acids in Humans: Alterations in Salt-Sensitive Normotensive Subjects. Hypertension 71:346-355
Sausville, Lindsay N; Gangadhariah, Mahesha H; Chiusa, Manuel et al. (2018) The Cytochrome P450 Slow Metabolizers CYP2C9*2 and CYP2C9*3 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production. Cancer Res 78:4865-4877
Garcia, Victor; Gilani, Ankit; Shkolnik, Brian et al. (2017) 20-HETE Signals Through G-Protein-Coupled Receptor GPR75 (Gq) to Affect Vascular Function and Trigger Hypertension. Circ Res 120:1776-1788
Guo, Zhijun; Sevrioukova, Irina F; Denisov, Ilia G et al. (2017) Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria. Cell Chem Biol 24:1259-1275.e6
Zhang, Hui; Falck, John R; Roman, Richard J et al. (2017) Upregulation of 20-HETE Synthetic Cytochrome P450 Isoforms by Oxygen-Glucose Deprivation in Cortical Neurons. Cell Mol Neurobiol 37:1279-1286
Gangadhariah, Mahesha H; Dieckmann, Blake W; Lantier, Louise et al. (2017) Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans. Diabetologia 60:1066-1075
Shuey, Megan M; Billings 4th, Frederic T; Wei, Shouzou et al. (2017) Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery. PLoS One 12:e0175292
Fan, Fan; Pabbidi, Mallikarjuna R; Ge, Ying et al. (2017) Knockdown of Add3 impairs the myogenic response of renal afferent arterioles and middle cerebral arteries. Am J Physiol Renal Physiol 312:F971-F981
Imig, J D (2016) Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function. Adv Pharmacol 77:105-41
Savas, Üzen; Wei, Shouzou; Hsu, Mei-Hui et al. (2016) 20-Hydroxyeicosatetraenoic Acid (HETE)-dependent Hypertension in Human Cytochrome P450 (CYP) 4A11 Transgenic Mice: NORMALIZATION OF BLOOD PRESSURE BY SODIUM RESTRICTION, HYDROCHLOROTHIAZIDE, OR BLOCKADE OF THE TYPE 1 ANGIOTENSIN II RECEPTOR. J Biol Chem 291:16904-19

Showing the most recent 10 out of 376 publications